New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
07:35 EDTPETXAratana Therapeutics initiates pivotal study for AT-001
Aratana Therapeutics announced the initiation of the pivotal field effectiveness study for AT-001, the company's innovative drug for treating pain in dogs with osteoarthritis. The randomized, blinded, multicenter pivotal study will enroll approximately 300 client-owned dogs with osteoarthritis, and will be conducted under a study protocol for which Aratana received concurrence from the FDA's Center for Veterinary Medicine. The primary endpoint will be a reduction in osteoarthritis pain compared to placebo, as indicated by the Canine Brief Pain Inventory scale, a well validated and widely used scoring system.
News For PETX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
08:29 EDTPETXAratana Therapeutics' AT-016 meets endpoint in dose confirmation study
Aratana Therapeutics' strategic partner VetStem Biopharma has shared positive results from a dose confirmation study of AT-016, an adipose-derived allogeneic stem cell product exclusively licensed to Aratana for the treatment of osteoarthritis pain in dogs. The double-blinded, multi-site, placebo-controlled field efficacy trial enrolled approximately 90 dogs with osteoarthritis. The dogs who received a single intra-articular injection of AT-016 demonstrated a statistically significant improvement in treatment versus placebo. The primary endpoint was treatment success based on the Client Specific Outcome Measurement on day 60. Based on current timelines, the final study report is being prepared for FDA submission and agreement on the pivotal field effectiveness study design. If approved by the FDA's Center for Veterinary Medicine, AT-016 could be commercially available in late-2017 or 2018.
July 29, 2015
10:00 EDTPETXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:47 EDTPETXAratana Therapeutics initiated with a Buy at Lake Street
Target $28.
July 27, 2015
07:18 EDTPETXAratana Therapeutics reports cats weight changes in AT-002 study
Subscribe for More Information
July 22, 2015
09:25 EDTPETXAratana Therapeutics updates canine monoclonal antibody product pipeline
Aratana Therapeutics provided an update on the development, manufacturing and commercialization of their monoclonal antibodies targeting canine B-cell lymphoma and canine T-cell lymphoma. AT-004 has received full licensure from the United States Department of Agriculture, and AT-005 has received conditional licensure from the USDA and Aratana continues to anticipate full licensure in 2015. Aratana has completed enrollment in its second designed to assess adding AT-005 to a multi-agent chemotherapy protocol for dogs with T-cell lymphoma. Results from two studies are expected by mid-2016. Aratana continues to make AT-005 commercially available through a T-cell Clinical Experience Program. Aratana expects to report the initial results of B-CEP and the mini B-CHOMP study results in mid-2016. Aratana anticipates that it will remain manufacturing constrained on AT-004 until late-2016. Aratana expects a limited commercialization through the T-CEP and B-CEP programs until late 2016 at which time a full commercial launch is anticipated.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use